Alzamend Neuro, Inc. — Director's Dealing 2022

Nov 21, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Alzamend Neuro, Inc. (ALZN)
CIK: 0001677077
Period of Report: 2022-11-18

Reporting Person: AULT MILTON C III (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-18	Common Stock	P	1000	$1.2890	Acquired	11038001	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2500000	Direct
Common Stock	14942984	Indirect
Common Stock	10000000	Indirect
Common Stock	325000	Indirect

Footnotes

F1: The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.2890. The range of purchase prices on the transaction date was $1.2883 to $1.29 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.

F2: Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of BitNile Holdings, Inc. ("BH"). Mr. Ault, the Executive Chairman of BH, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.

F3: Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.

F4: Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.

F5: Milton C. Ault, III, is the Manager of Ault Alpha GP LLC ("Ault GP") and Ault Capital Management LLC ("AC Management"). Ault GP and AC Management are the general partner and investment manager to Ault Alpha LP, respectively. As such, Mr. Ault is deemed to beneficially own the shares held by Ault Alpha LP.